biOasis Technologies Ord Shs V.BTI.H

RE:Looks like fuzzy is all in.

[prophetoffactz]

You may be able to add importantly to this list jd? With Biodexa Is xB3 potentially in the strongest hands it has ever been in to get out of this decade long quagmire that it has been in?

The new merged company, Biodexa:

1) Still has control of xB3. 
2) Has clinical trial infrastructure to advance clinical trials itself and enter into more significant strategic alliances.
3) Has US NASDAQ listing.
4) Has the backing of US Ladenberg Thalmann.
5) Has some cash and with additional deals potentially more cash soon. There is 1 1/2 months until the expiration of the J&J option. Neuremedy has an option that can be exercised and monitized. There are also potential milestone payments from partners.
6) Biodexa has multiple clinical stage assets that can support news flow and hard data valuation milestones while xB3 advances to the clinic over the next two years. 
7) Hunter is reaffirmed as xB3's lead asset in the merger. If Chiesi encountered a roadblock would Hunter, which is also an LSD, be nominated as xB3's lead assets? Chiesi recently submitted Fabry for US FDA approval and expects approval in 2023 making it a strategic player in the LSD space. Biodexa will be presenting preclinical Hunter data in Q2 2023. What's this new data about given the previous data BTI has presented? Do we have improved second-generation LSD asset to take on Denali which has helped prove LSDs in humans? Could Biodexa leap-frog Denali? Biodexa has the capability to advance clinical trials itself. Biodexa could enter a more substantive strategic deal with Chiesi in the LSD and even rare disease space. Oxyrane also has an interesting potential LSD opportunity.
8) Biodexa has cancer assets and expertise that could be used with xB3 that may support an interesting strategic alliance in cancer or combination therapies.